These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

803 related items for PubMed ID: 23256501

  • 1. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S, Chakravarty J.
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [Abstract] [Full Text] [Related]

  • 2. Current and emerging medications for the treatment of leishmaniasis.
    Chakravarty J, Sundar S.
    Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
    [Abstract] [Full Text] [Related]

  • 3. An update on pharmacotherapy for leishmaniasis.
    Sundar S, Chakravarty J.
    Expert Opin Pharmacother; 2015 Feb; 16(2):237-52. PubMed ID: 25346016
    [Abstract] [Full Text] [Related]

  • 4. Chemotherapeutics of visceral leishmaniasis: present and future developments.
    Sundar S, Singh A.
    Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of visceral leishmaniasis in children].
    Minodier P, Noël G, Blanc P, Uters M, Retornaz K, Garnier JM.
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
    Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.
    PLoS Negl Trop Dis; 2012 Feb; 6(5):e1657. PubMed ID: 22629478
    [Abstract] [Full Text] [Related]

  • 12. [Visceral leishmaniasis: new drugs].
    Minodier P, Robert S, Retornaz K, Garnier JM.
    Arch Pediatr; 2003 Dec; 10 Suppl 5():550s-556s. PubMed ID: 15022780
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D, Ramesh V, Verma S, Ramam M, Salotra P.
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract] [Full Text] [Related]

  • 15. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK, Sah AK, Shah DK, Sah P.
    JNMA J Nepal Med Assoc; 2013 Dec; 52(192):645-51. PubMed ID: 25327244
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN, Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D, Siddiqui NA, Verma RB, Das P.
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.